Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Int J Biol Macromol ; 174: 289-299, 2021 Mar 31.
Artículo en Inglés | MEDLINE | ID: mdl-33524482

RESUMEN

Capsaicin (CAP) is the main pungent component in capsicum fruits. Eating too much CAP leads to gastrointestinal injury. Previously, Qingke ß-glucan combined with ß-glucan-utilizing Lactobacillus plantarum S58 (LP.S58) ameliorated high fat-diet-induced obesity, but their effects on CAP-induced gastrointestinal injury have not been investigated. Our results showed that Qingke ß-glucan reduced the CAP-induced gastrointestinal injury in Kunming mice. The serum levels of inflammatory cytokines and gastrointestinal hormones, and the localized inflammation and the expression of EGF, EGFR, VEGF, and ZO-1 in the gastrointestinal tissues in CAP-treated mice were partly restored by Qingke ß-glucan. The CAP-induced increase in the abundances of proinflammatory intestinal bacteria was also reduced by Qingke ß-glucan. More importantly, we found that these beneficial effects of Qingke ß-glucan were markedly enhanced by ß-glucan-utilizing LP.S58 supplementation. Our study indicated that Qingke ß-glucan coupled with ß-glucan-utilizing LP.S58 relieved CAP-induced gastrointestinal injury.


Asunto(s)
Capsaicina/efectos adversos , Gastroenteritis/terapia , Glucanos/administración & dosificación , Hordeum/química , Lactobacillus plantarum/fisiología , Probióticos/administración & dosificación , Animales , Terapia Combinada , Citocinas/sangre , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Receptores ErbB/genética , Receptores ErbB/metabolismo , Gastroenteritis/inducido químicamente , Gastroenteritis/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Redes Reguladoras de Genes/efectos de los fármacos , Glucanos/metabolismo , Glucanos/farmacología , Lactobacillus plantarum/metabolismo , Masculino , Ratones , Extractos Vegetales/administración & dosificación , Extractos Vegetales/metabolismo , Extractos Vegetales/farmacología , Probióticos/farmacología , Resultado del Tratamiento , Proteína de la Zonula Occludens-1/genética , Proteína de la Zonula Occludens-1/metabolismo
2.
Acta Biochim Pol ; 67(3): 393-399, 2020 Sep 18.
Artículo en Inglés | MEDLINE | ID: mdl-32945647

RESUMEN

We compared fecal samples from responders and non-responders to administration of Lactobacillus reuteri DSM 17938. Data for this post hoc analysis were collected from an RCT assessing the efficacy of L. reuteri for the management of acute gastroenteritis. Responders were defined as subjects with diarrhea lasting no longer than 48 h. 44 children (17 responders and 27 non-responders) were analyzed. There were no differences in clinical characteristics and gut colonization between both groups. In the responder group, there were significantly lower levels of five metabolites before beginning of the intervention: lactate, choline, ethanol, creatine, and formate. The fecal calprotectin level did not differ between groups prior to the intervention, but its level was significantly lower after intervention in the responder group. Possibly, the responder group with a "metabolic niche", including lower level of metabolites, especially lactate, that are potential products of Lactobacillus genus, would determine the response to probiotic treatment. These findings need to be confirmed, but identification of some differences in the fecal metabolomics and the calprotectin level suggests that further studies are warranted.


Asunto(s)
Diarrea/dietoterapia , Suplementos Dietéticos/microbiología , Heces/química , Heces/microbiología , Gastroenteritis/dietoterapia , Limosilactobacillus reuteri/metabolismo , Probióticos/uso terapéutico , Enfermedad Aguda , Preescolar , Diarrea/metabolismo , Método Doble Ciego , Femenino , Gastroenteritis/metabolismo , Humanos , Lactante , Complejo de Antígeno L1 de Leucocito/análisis , Complejo de Antígeno L1 de Leucocito/metabolismo , Masculino , Metaboloma , Resultado del Tratamiento
3.
Curr Opin Pharmacol ; 43: 81-86, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30218940

RESUMEN

The evolving policies regarding the use of therapeutic Cannabis have steadily increased the public interest in its use as a complementary and alternative medicine in several disorders, including inflammatory bowel disease. Endocannabinoids represent both an appealing therapeutic strategy and a captivating scientific dilemma. Results from clinical trials have to be carefully interpreted owing to possible reporting-biases related to cannabinoids psychotropic effects. Moreover, discriminating between symptomatic improvement and the real gain on the underlying inflammatory process is often challenging. This review summarizes the advances and latest discovery in this ever-changing field of investigation, highlighting the main limitations in the current use of these drugs in clinical practice and the possible future perspectives to overcome these flaws.


Asunto(s)
Antiinflamatorios/uso terapéutico , Agonistas de Receptores de Cannabinoides/uso terapéutico , Endocannabinoides/uso terapéutico , Gastroenteritis/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Tracto Gastrointestinal/efectos de los fármacos , Receptores de Cannabinoides/efectos de los fármacos , Animales , Antiinflamatorios/efectos adversos , Agonistas de Receptores de Cannabinoides/efectos adversos , Endocannabinoides/efectos adversos , Endocannabinoides/metabolismo , Gastroenteritis/diagnóstico , Gastroenteritis/metabolismo , Gastroenteritis/fisiopatología , Fármacos Gastrointestinales/efectos adversos , Tracto Gastrointestinal/metabolismo , Tracto Gastrointestinal/fisiopatología , Humanos , Ligandos , Receptores de Cannabinoides/metabolismo , Factores de Riesgo , Transducción de Señal/efectos de los fármacos , Resultado del Tratamiento
4.
Sci Rep ; 6: 35813, 2016 10 25.
Artículo en Inglés | MEDLINE | ID: mdl-27779218

RESUMEN

Anorexia nervosa (AN) is associated with low-grade systemic inflammation and altered gut microbiota. However, the molecular origin of the inflammation remains unknown. Toll-like receptors are key regulators of innate immune response and their activation seems also to be involved in the control of food intake. We used activity-based anorexia (ABA) model to investigate the role of TLR4 and its contribution in anorexia-associated low-grade inflammation. Here, we found that ABA affected early the intestinal inflammatory status and the hypothalamic response. Indeed, TLR4 was upregulated both on colonic epithelial cells and intestinal macrophages, leading to elevated downstream mucosal cytokine production. These mucosal changes occurred earlier than hypothalamic changes driving to increased levels of IL-1ß and IL-1R1 as well as increased levels of plasma corticosterone. Paradoxically, TLR4-deficient mice exhibited greater vulnerability to ABA with increased mortality rate, suggesting a major contribution of TLR4-mediated responses during ABA-induced weight loss.


Asunto(s)
Anorexia/fisiopatología , Gastroenteritis/metabolismo , Receptor Toll-Like 4/metabolismo , Animales , Anorexia/metabolismo , Colon/metabolismo , Colon/fisiopatología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Femenino , Gastroenteritis/inmunología , Hipotálamo/inmunología , Hipotálamo/fisiopatología , Mucosa Intestinal/metabolismo , Ratones Endogámicos C57BL , Ratones Noqueados , Condicionamiento Físico Animal , Transducción de Señal , Receptor Toll-Like 4/genética , Pérdida de Peso/genética
5.
Br J Nutr ; 107(11): 1570-90, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21914238

RESUMEN

The effects of combining soyasaponins with plant ingredients on intestinal function and fish health were investigated in an 80 d study with Atlantic salmon (270 g) distributed thirty each into twenty-four tanks with seawater. Soyasaponins were supplemented (2 g/kg) to diets with maize gluten (MG), pea protein concentrate (PPC) and sunflower (SFM), rapeseed (RSM) or horsebean meals. A diet with soyabean meal (SBM) and another with wheat gluten and soyasaponins served as reference diets. Marked soyasaponin effects were observed when combined with PPC. This combination induced inflammation in the distal intestine (DI) similar to SBM, reduced feed intake, apparent digestibility of lipid, most amino acids and ash, decreased bile salt levels in intestinal chyme and decreased leucine aminopeptidase (LAP) activity but increased trypsin activity in the DI. No enteritis was observed in other diet groups, but small consistent negative soyasaponin effects were seen on lipid and fatty acid digestibility, faecal DM and LAP activity of the DI. Soyasaponin combination with RSM reduced digestibility of all nutrients including minerals. The mineral effect was also seen for SFM, whereas with MG and SFM a positive soyasaponin effect on feed intake was observed. Caution should be exercised to avoid ingredient combinations giving high saponin levels, a condition that appears to be a key factor in diet-induced enteritis together with certain plant ingredients.


Asunto(s)
Alimentación Animal/efectos adversos , Dieta/veterinaria , Enfermedades de los Peces/etiología , Gastroenteritis/veterinaria , Salmo salar/crecimiento & desarrollo , Saponinas/efectos adversos , Alimentación Animal/análisis , Animales , Acuicultura , Dieta/efectos adversos , Grasas de la Dieta/metabolismo , Proteínas en la Dieta/metabolismo , Digestión , Ingestión de Energía , Enfermedades de los Peces/inmunología , Enfermedades de los Peces/metabolismo , Enfermedades de los Peces/patología , Proteínas de Peces/metabolismo , Gastroenteritis/etiología , Gastroenteritis/metabolismo , Gastroenteritis/patología , Intestino Grueso/enzimología , Intestino Grueso/inmunología , Intestino Grueso/patología , Leucil Aminopeptidasa/metabolismo , Pisum sativum/efectos adversos , Pisum sativum/química , Proteínas de Plantas/metabolismo , Salmo salar/inmunología , Salmo salar/metabolismo , Semillas/efectos adversos , Semillas/química , Glycine max/efectos adversos , Glycine max/química , Aumento de Peso
6.
Chem Biol Interact ; 192(3): 193-200, 2011 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-21453689

RESUMEN

Colon cancer is the major health hazard related with high mortality and it is a pathological consequence of persistent oxidative stress and inflammation. Farnesol, an isoprenoid alcohol, has been shown to possess antioxidant, anti-inflammatory and chemopreventive properties. The present study was performed to evaluate the protective efficacy of farnesol against 1,2-dimethylhydrazine (DMH) induced oxidative stress, inflammatory response and apoptotic tissue damage. Farnesol was administered once daily for seven consecutive days at the doses of 50 and 100 mg/kg body weight in corn oil. On day 7, a single injection of DMH was given subcutaneously in the groin at the dose of 40 mg/kg body weight. Protective effects of farnesol were assessed by using caspase-3 activity, tissue lipid peroxidation (LPO) and antioxidant status as end point markers. Further strengthening was evident on histopathological observations used to assess the protective efficacy of farnesol. Prophylactic treatment with farnesol significantly ameliorates DMH induced oxidative damage by diminishing the tissue LPO accompanied by increase in enzymatic viz., superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione reductase (GR), glutathione-S-transferase (GST) and quinone reductase (QR) and non-enzymatic viz., reduced glutathione (GSH) antioxidant status. Farnesol supplementation significantly decreased caspase-3 activity in colonic tissue. Histological findings also revealed that pretreatment with farnesol significantly reduced the severity of submucosal edema, regional destruction of the mucosal layer and intense infiltration of the inflammatory cells in mucosal and submucosal layers of the colon. The data of the present study suggest that farnesol effectively suppress DMH induced colonic mucosal damage by ameliorating oxidative stress, inflammatory and apoptotic responses.


Asunto(s)
1,2-Dimetilhidrazina/toxicidad , Antiinflamatorios/farmacología , Carcinógenos/toxicidad , Colon/efectos de los fármacos , Farnesol/farmacología , Gastroenteritis/tratamiento farmacológico , Animales , Antiinflamatorios/uso terapéutico , Anticarcinógenos/farmacología , Anticarcinógenos/uso terapéutico , Apoptosis/efectos de los fármacos , Caspasa 3/metabolismo , Catalasa/metabolismo , Colon/metabolismo , Colon/patología , Farnesol/uso terapéutico , Gastroenteritis/inducido químicamente , Gastroenteritis/metabolismo , Glutatión/metabolismo , Glutatión Peroxidasa/metabolismo , Glutatión Reductasa/metabolismo , Glutatión Transferasa/metabolismo , Peróxido de Hidrógeno/metabolismo , Masculino , Malondialdehído/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Wistar , Superóxido Dismutasa/metabolismo
7.
Vitam Horm ; 86: 353-66, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21419279

RESUMEN

The intestinal barrier is one of the most dynamic surfaces of the body. It is here where a single layer of epithelial cells mediates the intricate encounters that occur between the host's immune system and a multitude of potential threats present in the intestinal lumen. Several key factors play an important role in the final outcome of this interaction, including the state of oxidative stress, the level of activation of the immune cells, and the integrity of the epithelial barrier. This chapter describes the main evidence demonstrating the impact that l-carnitine has on each of these factors. These findings, combined with the demonstrated safety profile of l-carnitine, underscore the potential therapeutic value of l-carnitine supplementation in humans suffering from intestinal inflammation and highlight the functional data supporting an association between Crohn's disease and mutations in the l-carnitine transporter genes.


Asunto(s)
Carnitina/fisiología , Gastroenteritis/metabolismo , Enfermedades Intestinales/metabolismo , Animales , Carnitina/deficiencia , Carnitina/uso terapéutico , Suplementos Dietéticos , Gastroenteritis/etiología , Gastroenteritis/terapia , Humanos , Terapia de Inmunosupresión , Enfermedades Intestinales/etiología , Enfermedades Intestinales/terapia , Deficiencia de Vitamina B/metabolismo , Deficiencia de Vitamina B/fisiopatología , Deficiencia de Vitamina B/terapia
8.
J Pediatr Gastroenterol Nutr ; 48 Suppl 2: S58-62, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19300128

RESUMEN

The colon is actively implicated in intestinal infections not only as a target of enteric pathogens and their products but also as a target organ for treatment. In the presence of diarrhea, both of osmotic and secretory nature, the colon reacts with homeostatic mechanisms to increase ion absorption. These mechanisms can be effectively exploited to decrease fluid discharge. A model of intestinal infections using rotavirus (RV) in colonic cells was set up and used to define a dual model of secretory and osmotic diarrhea in sequence. Using this model, antidiarrheal drugs were tested, namely zinc and the enkephalinase inhibitor racecadotril. Zinc was able to decrease the enterotoxic activity responsible for secretory diarrhea. It also inhibited the cytotoxic effect of RV. The mechanism of zinc was related at least in part to the activation of MAPK activity, but also a direct antiviral effect was observed. Racecadotril showed a potent and selective inhibition of active secretion, being particularly effective in the first phase of RV diarrhea. The use of drugs active at the colonic level, therefore, offers effective options to treat intestinal infections in childhood. In addition, the colon is the natural site of colonic microflora, a target of probiotic therapy, which is the first line of approach recommended by the European Society for Paediatric Gastroenterology, Hepatology and Nutrition to treat infectious diarrhea.


Asunto(s)
Antidiarreicos/uso terapéutico , Colon/efectos de los fármacos , Diarrea/tratamiento farmacológico , Gastroenteritis/tratamiento farmacológico , Infecciones por Rotavirus/tratamiento farmacológico , Tiorfan/análogos & derivados , Zinc/uso terapéutico , Enfermedad Aguda , Células CACO-2 , Colon/metabolismo , Colon/virología , Diarrea/metabolismo , Diarrea/virología , Evaluación Preclínica de Medicamentos , Gastroenteritis/metabolismo , Gastroenteritis/virología , Humanos , Absorción Intestinal/efectos de los fármacos , Infecciones por Rotavirus/metabolismo , Tiorfan/uso terapéutico
9.
Gastroenterology ; 133(4): 1219-28, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17919496

RESUMEN

BACKGROUND & AIMS: We previously showed that intestinal inflammation is reduced by electrical stimulation of the efferent vagus nerve, which prevents postoperative ileus in mice. We propose that this cholinergic anti-inflammatory pathway is mediated via alpha7 nicotinic acetylcholine receptors expressed on macrophages. The aim of this study was to evaluate pharmacologic activation of the cholinergic anti-inflammatory pathway in a mouse model for postoperative ileus using the alpha7 nicotinic acetylcholine receptor-agonist AR-R17779. METHODS: Mice were pretreated with vehicle, nicotine, or AR-R17779 20 minutes before a laparotomy (L) or intestinal manipulation (IM). Twenty-four hours thereafter gastric emptying was determined using scintigraphy and intestinal muscle inflammation was quantified. Nuclear factor-kappaB transcriptional activity and cytokine production was assayed in peritoneal macrophages. RESULTS: Twenty-four hours after surgery IM led to a delayed gastric emptying compared with L (gastric retention: L(saline) 14% +/- 4% vs IM(saline) 38% +/- 10%, P = .04). Pretreatment with AR-R17779 prevented delayed gastric emptying (IM(AR-R17779) 15% +/- 4%, P = .03). IM elicited inflammatory cell recruitment (L(saline) 50 +/- 8 vs IM(saline) 434 +/- 71 cells/mm(2), P = .001) which was reduced by AR-R17779 pretreatment (IM(AR-R17779) 231 +/- 32 cells/mm(2), P = .04). An equimolar dose of nicotine was not tolerated. Subdiaphragmal vagotomy did not affect the anti-inflammatory properties of AR-R17779. In peritoneal macrophages, both nicotinic agonists reduced nuclear factor kappaB transcriptional activity and proinflammatory cytokine production, with nicotine being more effective than AR-R17779. CONCLUSIONS: AR-R17779 treatment potently prevents postoperative ileus, whereas toxicity limits nicotine administration to ineffective doses. Our data further imply that nicotinic inhibition of macrophage activation may involve other receptors in addition to alpha7 nicotinic acetylcholine receptor.


Asunto(s)
Antiinflamatorios/farmacología , Hidrocarburos Aromáticos con Puentes/farmacología , Gastroenteritis/prevención & control , Ileus/prevención & control , Intestinos/efectos de los fármacos , Macrófagos Peritoneales/efectos de los fármacos , Agonistas Nicotínicos/farmacología , Complicaciones Posoperatorias/prevención & control , Compuestos de Espiro/farmacología , Animales , Antiinflamatorios/uso terapéutico , Antiinflamatorios/toxicidad , Hidrocarburos Aromáticos con Puentes/uso terapéutico , Células Cultivadas , Citocinas/metabolismo , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Terapia por Estimulación Eléctrica , Femenino , Vaciamiento Gástrico/efectos de los fármacos , Gastroenteritis/metabolismo , Gastroenteritis/fisiopatología , Ileus/metabolismo , Ileus/fisiopatología , Intestinos/inervación , Intestinos/fisiopatología , Intestinos/cirugía , Macrófagos Peritoneales/metabolismo , Ratones , Ratones Endogámicos BALB C , FN-kappa B/metabolismo , Nicotina/farmacología , Nicotina/toxicidad , Agonistas Nicotínicos/uso terapéutico , Agonistas Nicotínicos/toxicidad , Complicaciones Posoperatorias/metabolismo , Complicaciones Posoperatorias/fisiopatología , Receptores Nicotínicos/efectos de los fármacos , Receptores Nicotínicos/metabolismo , Compuestos de Espiro/uso terapéutico , Transcripción Genética/efectos de los fármacos , Vagotomía , Nervio Vago/cirugía , Receptor Nicotínico de Acetilcolina alfa 7
10.
Gastroenterology ; 133(4): 1370-3, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17919507
11.
J Pediatr ; 118(4 Pt 1): 526-30, 1991 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-2007925

RESUMEN

To determine whether rice cereal could be used to complement a cow milk-based diet in the nutritional management of infants with acute diarrhea, we assessed its digestion and absorption in eight affected male infants, 69 to 131 days of age. They received cow milk formula with 5.4% lactose (diluted 1:1 with water and precooked rice cereal) 5 to 22 hours after admission and rehydration. The first feeding consisted of milk diluted with carbon 13-enriched rice cereal. A 48-hour fecal collection and balance study was performed. Rice cereal was reasonably well absorbed (84.0% to 95.8%) by seven of the eight infants. The study was repeated in seven of the infants after they had recovered. Our results indicated that rice cereal is well absorbed by young infants with acute diarrhea and that it is an adequate nutrient supplement for this patient population.


Asunto(s)
Gastroenteritis/metabolismo , Alimentos Infantiles , Absorción Intestinal , Oryza , Enfermedad Aguda , Animales , Isótopos de Carbono , Diarrea Infantil/metabolismo , Diarrea Infantil/terapia , Ingestión de Alimentos , Heces , Humanos , Lactante , Masculino , Leche
12.
Am J Clin Nutr ; 51(6): 1088-92, 1990 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-2349923

RESUMEN

To evaluate the effect of copper supplementation during recovery from acute diarrhea, we randomly assigned 14 hospitalized infants to receive either 80 micrograms copper sulfate.kg body wt-1.d-1 or a placebo. Metabolic balance and plasma copper and zinc concentrations were measured before randomization (period 1) and 6 d after admission (period 2). Fifteen control subjects were studied after respiratory illness. Fecal copper was not affected by supplementation; fecal zinc during period 2 rose significantly only in the copper-supplemented group. Copper retention was significantly higher in the supplemented infants; plasma concentrations increased for period 2 but were similar to those in the placebo group. Zinc concentrations improved over time in both groups but zinc retention was higher in the placebo group for period 2. A significant interference by copper supplementation on zinc absorption was noted. Copper supplementation during the early phase of recovery from diarrhea is not recommended.


Asunto(s)
Cobre/metabolismo , Diarrea Infantil/metabolismo , Heces/análisis , Gastroenteritis/metabolismo , Zinc/metabolismo , Enfermedad Aguda , Cobre/sangre , Cobre/farmacología , Humanos , Lactante , Masculino , Fenómenos Fisiológicos de la Nutrición , Distribución Aleatoria , Zinc/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA